Abstract
The dual-variable domain immunoglobulin ABBV-257 binds tumor necrosis factor-α and interleukin 17A. Following single ascending doses ( 0.3, 1.0, and 3.0 mg/kg intravenously; 0.3 and 3.0 mg/kg subcutaneously) in a randomized, double-blind, placebo-controlled study in healthy subjects (n = 40; n = 29 evaluated for pharmacokinetics), maximum observed serum concentration (Cmax ) increased dose-proportionally, whereas area under the serum concentration-versus-time curve trended to more than dose-proportional increase. Absolute subcutaneous bioavailability was ∼80%, and the time to Cmax (tmax ) occurred 6 to 8 days after subcutaneous administration. The terminal-phase harmonic mean elimination half-life (t½ ) ranged from 5.5 to 11 days following intravenous and subcutaneous administration. In another randomized, placebo-controlled study, rheumatoid arthritis (RA) patients (n = 8) received ABBV-257 30 mg/kg subcutaneously every other week for 8 weeks. Following the fourth dose, Cmax was 7.69 μg/mL, and tmax occurred ∼4 days after dosing; t½ was ∼16 days. Most individuals (single-dose study, 97%; multiple-dose study, 83%) developed antidrug antibodies (ADAs). Generally, subjects with higher ADA titers had shorter ABBV-257 t½ and lower ...Continue Reading
References
May 30, 2002·Nature Reviews. Immunology·Marc Feldmann
Dec 31, 2003·The Journal of Biological Chemistry·Paul R HintonNaoya Tsurushita
Dec 14, 2011·The New England Journal of Medicine·Iain B McInnes, Georg Schett
Jan 25, 2012·PloS One·Kalle J AaltonenMarja Blom
Jun 29, 2012·Rheumatology·Ernest Choy
Jan 10, 2014·Rheumatology·Daniel E Furst, Paul Emery
Aug 21, 2016·Lancet·Quan Dong NguyenAntoine P Brézin
Sep 8, 2016·The New England Journal of Medicine·Glenn J JaffeEric B Suhler
Sep 28, 2016·Drug Design, Development and Therapy·Min Wei, Dongmei Duan
Jan 10, 2017·Clinical Pharmacokinetics·Ahmed NaderNael Mostafa
Jul 27, 2017·Clinical Pharmacokinetics·Amit KhatriAhmed A Othman
Sep 25, 2017·Arthritis & Rheumatology·Roy M FleischmannRobert J Padley
Jan 25, 2018·Journal of Clinical Pharmacology·Amit Khatri, Ahmed A Othman
Jun 2, 2018·Arthritis & Rheumatology·Mark C GenoveseRobert J Padley
Jun 2, 2018·Arthritis & Rheumatology·Philip J MeaseJohn Liu